Selvita to Release the Most Recent Results from its Oncology Programs at the 2011 American Association for Cancer Research-European Organization for Research and Treatment of Cancer-National Cancer Institute Molecular Targets and Cancer Therapeutics Confe
Published: Oct 24, 2011
Data presented during this conference will include new results from the SEL24 program, a group of specific inhibitors of Pim-1 kinase, as well as the first data from SEL120 program, a potentially first in class kinase inhibitor.
A poster presentation entitled "Novel Pim kinase inhibitors for treatment of hematological malignancies and solid tumors" is scheduled to be presented at the poster session A, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 1" on Sunday, November 13th, 2011 from 12:30 PM - 2:30 PM, at the West Hall, Level One, Moscone Center West (Abstract #: A243)
A poster presentation entitled " Antitumor activity of SEL120: An orally available small-molecule inhibitor of Haspin kinase, for standalone and combination therapy with AuroraB inhibitors in colorectal cancer" is scheduled to be presented at the poster session B, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 2" Monday, November 14th, 2011 from 12:30 PM - 2:30 PM, at the West Hall, Level One, Moscone Center West (Abstract # B242).
“Current and further development of both SEL24 and SEL120 program, presented at the AACR-EORTC-NCI conference, was made possible thanks to the substantial investment received by Selvita through private placement and the debut on the NewConnect market in July 2011– said Dr Nicolas Beuzen, Selvita’s Chief Scientific Officer. SEL24 is currently at the lead optimization stage, with first clinical trials to be initiated in 2012, while SEL120 is currently in the early phase of discovery research. Selvita’s strategy assumes sales of both programs, SEL24 in 2012 and SEL120 in the following years, which will allow the company to break-even in 2012.”
Selvita is a Polish, biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services. It was established and 2007 and currently employs 125 scientists, including 45 PhDs. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2012. The most advanced programs at Selvita are SEL103 for the symptomatic treatment of Alzheimer’s disease, partnered with Orion Pharma, and SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in solid and hematopoietic tumors. Additional information about Selvita can be found on http://www.selvita.com/.
+48 12 297 47 31